Forest Expects Lexapro To Lead Market By ’05; Will Re-Launch In GAD In ’04

Forest expects its anti-depressant Lexapro (escitalopram) to lead the selective serotonin reuptake inhibitor market by 2005

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet